tbuckley/cabot-search huggingface dataset:
Abstract 9071: Prognosis of Elderly Non-Valvular Atrial Fibrillation Patients Stratified by B-type Natriuretic Peptide Concentration: A Subanalysis of Data from the ELDERCARE-AF Trial
Authors: Osamu Okazaki, Yorihiko Higashino, Koichi Yokoya, Yoshimori An, Kimihiko Tanizawa, Yuki Imamura, Takuya Hayashi, Masaharu Akao, Ken Okumura, Takeshi Yamashita
Journal: Circulation (2021)

Introduction: B-type natriuretic peptide (BNP) is a known predictor of prognosis and disease severity in patients with heart failure. However, only limited data are available on the relation between BNP and outcomes in very elderly (age, ≥ 80 years) patients ineligible for standard anticoagulation with non-valvular atrial fibrillation (NVAF). Therefore we evaluated the prognostic and therapeutic outcomes of very elderly Japanese NVAF patients stratified by BNP concentration. Methods: This was a subanalysis of data from ELDERCARE-AF, a multicenter, randomized, double-blind, placebo-controlled phase 3 study of edoxaban 15 mg (once daily) in very elderly Japanese NVAF patients considered ineligible for standard anticoagulant treatment. Patients were stratified according to BNP concentration at enrollment, and their outcomes were compared. The primary efficacy endpoint was stroke or systemic embolism (SSE). The primary safety endpoint was major bleeding. Results: A total of 984 patients (mean age, 86.6 years) were randomized to edoxaban 15mg ( n = 492) or placebo ( n = 492). BNP concentration at enrollment was &lt; 200 pg/mL (low), 200 to &lt; 400 pg/mL (moderate), and ≥ 400 pg/mL (high) in 428, 300, and 256 patients, respectively. Mean CHADS 2 score was 2.9 in the low BNP and 3.2 in the moderate and high BNP groups. The incidences of SSE were 1.2%/patient-year (7/428), 5.9%/patient-year (24/300), and 8.6%/patient-year (28/256) in the low, moderate, and high BNP groups, respectively: unadjusted HR = 5.03 (95% confidential interval [CI], 2.17-11.67), P = 0.0002, for low versus moderate BNP; unadjusted HR = 7.07 (3.09-16.18), P &lt; 0.0001, for low versus high BNP. No significant intergroup differences were found for the incidence of major bleeding. Edoxaban 15mg was superior to placebo in preventing SSE in the moderate and high BNP groups: unadjusted HR, 0.27 (0.10-0.73), P &lt; 0.01, and unadjusted HR, 0.34 (0.15-0.81), P &lt; 0.05, respectively. There was no significant difference in major bleeding between the edoxaban 15mg and placebo groups. Conclusions: In very elderly NVAF patients, BNP concentration was positively related to the incidence of SSE, and edoxaban 15mg had a preventive effect, regardless of BNP concentration.
Central Nervous System Involvement in Extranodal Natural Killer/T-Cell Lymphoma: Case Series
Authors: Qingqing Cai, Jinni Wang, Yu Fang, Ning Su, Shuyun Ma, Jun Cai, Yuchen Zhang, Xiaopeng Tian, Huiqiang Huang, Zhiming Li, He Huang, Yi Xia, Panpan Liu
Journal: Blood (2021)
Deficiency of the E3 Ligase Hoip Impairs Adult Hematopoiesis and Myeloid Leukemia
Authors: Koji Jimbo, Shuhei Koide, Takahiro Ito, Arinobu Tojo, Katsuhiro Sasaki, Kazuhiro Iwai, Atsushi Iwama, Yasuhito Nannya, Takaaki Konuma
Journal: Blood (2021)
Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method
Authors: Prashant Nasa, Elie Azoulay, Arunaloke Chakrabarti, Jigeeshu V Divatia, Ravi Jain, Camilla Rodrigues, Victor D Rosenthal, Waleed Alhazzani, Yaseen M Arabi, Jan Bakker, Matteo Bassetti, Jan De Waele, George Dimopoulos, Bin Du, Sharon Einav, Laura Evans, Simon Finfer, Claude Guérin, Naomi E Hammond, Samir Jaber, Ruth M Kleinpell, Younsuck Koh, Marin Kollef, Mitchell M Levy, Flavia R Machado, Jordi Mancebo, Ignacio Martin-Loeches, Mervyn Mer, Michael S Niederman, Paolo Pelosi, Anders Perner, John V Peter, Jason Phua, Lise Piquilloud, Mathias W Pletz, Andrew Rhodes, Marcus J Schultz, Mervyn Singer, Jéan-François Timsit, Balasubramanian Venkatesh, Jean-Louis Vincent, Tobias Welte, Sheila N Myatra
Journal: The Lancet Infectious Diseases (2021)
Uncoupling p53 from an Embryonic Regulome Exhausts Quiescent CML Stem Cells through Inhibition of a HIF1alpha Molecular Program
Authors: Mary T Scott, Wei Liu, Rebecca Mitchell, Cassie Clarke, Hassan Almasoudi, Felix Warren, Ross Kinstrie, Karen Dunn, John Pritchard, Mark E Drotar, Alison M Michie, Heather G Jørgensen, Brian Higgins, Mhairi Copland, David Vetrie
Journal: Blood (2021)
Loss of TREM2 function increases amyloid seeding but reduces plaque-associated ApoE
Authors: Samira Parhizkar, Thomas Arzberger, Matthias Brendel, Gernot Kleinberger, Maximilian Deussing, Carola Focke, Brigitte Nuscher, Monica Xiong, Alireza Ghasemigharagoz, Natalie Katzmarski, Susanne Krasemann, Stefan F. Lichtenthaler, Stephan A. Müller, Alessio Colombo, Laura Sebastian Monasor, Sabina Tahirovic, Jochen Herms, Michael Willem, Nadine Pettkus, Oleg Butovsky, Peter Bartenstein, Dieter Edbauer, Axel Rominger, Ali Ertürk, Stefan A. Grathwohl, Jonas J. Neher, David M. Holtzman, Melanie Meyer-Luehmann, Christian Haass
Journal: Nature Neuroscience (2018)
Abstract 8917: Ankle-Brachial Index and Risk of Sudden Cardiac Death in the Community: The Atherosclerosis Risk in Communities (ARIC) Study
Authors: Takeki Suzuki, Xiaoqian Zhu, Selcuk Adabag, Kuni Matsushita, Kenneth R Butler, Michael Griswold, Alvaro Alonso, Wayne D Rosamond, Nona Sotoodehnia, Thomas Mosley
Journal: Circulation (2021)

Introduction: Sudden cardiac death (SCD) is an important public health problem. About 356,000 people suffer SCD in the U.S., accounting for 15% of all deaths. The ankle-brachial index (ABI) is a simple, non-invasive measure of subclinical atherosclerosis. The aim of this study was to determine the relation between ABI and SCD in a middle-aged biracial general population. Methods: All ARIC (Atherosclerosis Risk in Communities) study subjects with a documented ABI measurement between 1987 and 1989 were included in the study. ABI was categorized as abnormal (≤0.9), borderline (0.9-1), normal [1-1.4], and non-compressible (&gt;1.4). SCD was defined as a sudden pulseless condition presumed to be caused by a ventricular tachyarrhythmia in a previously stable individual. All SCD cases were adjudicated by a committee of cardiac electrophysiologists, cardiologists, and internists. Results: Of the 15,135 participants followed for a median of 23.5 years, 558 (3.7%) developed SCD (1.96 cases per 1000 person-years). Abnormal or borderline ABIs were associated with an elevated risk of SCD (HRs with 95 % CIs 2.27 [1.64-3.14] and 1.52 [1.17-1.96], respectively) in comparison to normal ABI. The association between abnormal ABI and SCD remained significant after adjustment for traditional cardiovascular risk factors, but not for borderline ABI (HR 1.63 [1.15-2.32] and 1.24 [0.94-1.63]) (Table). Conclusions: Abnormal ABI is independently associated with risk of SCD in a biracial general population. ABI could be incorporated into a future risk SCD prediction model.
Abstract PO-019: Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity
Authors: Bhalchandra Mirlekar, Yuliya Pylayeva-Gupta
Journal: Cancer Research (2021)

Abstract B cells frequently infiltrate human tumors, and the intra-tumoral abundance of plasma cells can correlate with improved patient prognosis. However, many tumors are devoid of plasma B cells, and strategies to enhance anti-tumor B cell responses are needed. We report the existence of a negative regulatory signaling network that reprograms naïve B cells in pancreatic cancer to antagonize anti-tumor plasma B cells. This network is driven by IL-35-mediated STAT3 activation, which directly stimulates upregulation of the pioneer transcription factors Pax5 and Bcl6 in naïve B cells and impedes plasma cell differentiation while simultaneously activating regulatory B cell phenotypes. Significantly, inhibition of Bcl6 reversed this tumor-associated reprogramming of naïve B cells, enabling intra-tumoral accumulation of plasma cells, and reduced tumor growth. Our data provide evidence that B cell dysfunction in cancer involves a potentially targetable suppression program that alters the differentiation potential of naïve B cells. Citation Format: Bhalchandra Mirlekar, Yuliya Pylayeva-Gupta. Reprogramming of naïve B cells in pancreatic cancer subverts humoral immunity [abstract]. In: Proceedings of the AACR Virtual Special Conference on Pancreatic Cancer; 2021 Sep 29-30. Philadelphia (PA): AACR; Cancer Res 2021;81(22 Suppl):Abstract nr PO-019.
Family history of plasma cell disorders is associated with improved survival in MGUS, multiple myeloma, and systemic AL amyloidosis
Authors: Alissa Visram, Celine Vachon, Linda B. Baughn, Dirk Larson, James Smadbeck, Angela Dispenzieri, Prashant Kapoor, Martha Q. Lacy, Morie A. Gertz, Francis K. Buadi, Suzanne R. Hayman, David Dingli, Taxiarchis Kourelis, Wilson Gonsalves, Rahma Warsame, Eli Muchtar, Nelson Leung, Robert A. Kyle, S. Vincent Rajkumar, Shaji Kumar
Journal: Leukemia (2021)
Abstract 9427: The Use of Cardiac Device Remote Monitoring in the Covid-19 Era of Telehealth Outpatient Medicine
Authors: Edmond Wong, John Z Xie, Kevin Rajakariar, Kevin Masman, Joris Mekel, Voltaire Nadurata
Journal: Circulation (2021)

Background and Aim: During the Covid-19 pandemic, outpatient care has utilised telemedicine reviews for cardiac follow-up. We assessed the safety of remote monitoring in context with telehealth medicine for such patients. Methods: A retrospective analysis was performed on cardiology pacing clinic patients at a hospital in Victoria, Australia, between March and September 2020. Patients were stratified into those who had face-to-face physician review, in-person cardiac technician review, and telemedicine consultation. Results: We identified 408 patients (65% male, age 65 ± 14 years), of whom 230 received telehealth consultation, 115 had technician-only reviews, and 63 had face-to-face physician review. There was no significant difference in baseline demographics. Remote monitors were used in 52% (n=120) of the telehealth cohort. Ventricular arrhythmias were seen in 1.3% (n=3) and 0.9% (n=1) during telehealth and technician review groups respectively, with none seen in the physician group (p=0.642). New atrial fibrillation (AF) was seen in 5.3% (n=12), 8.1% (n=5), and 3.5% (n=4) of groups respectively (p=0.421). Hospital admissions within one month of consultation occurred in 3.1% (n=7), 19% (n=12) and 7% (n=8) of the telemedicine review, physician review, and technician review groups respectively (p&lt;0.001). Of the 73 patients who had cardiac devices implanted, wound issues including haematoma and infection were identified in 3.5% (n=4) of the technician interrogation cohort, 1.6% (n=1) receiving face-to-face clinician review, and none in the telemedicine cohort (p=0.021).We identified 1.8% (n=4), 6.5% (n=4) and 8% (n=7) of patients who had reached elective replacement interval (ERI) in telemedicine, physician review and technician reviews respectively (p=0.036). Conclusion: Our study demonstrated no difference in detection of new AF or ventricular tachyarrhythmias between telemedicine and face-to-face consultations. Contrastingly, telemedicine reviews were associated with reduced detection of ERI, less detection of wound complications, compared to patients receiving in-hospital device interrogation. Randomised studies are required to determine the true impact of telemedicine on these outcomes.
ACUTE Lymphoblastic Leukemia (ALL) and COVID-19 Infection. a Campus ALL Report
Authors: Sabina Chiaretti, Massimiliano Bonifacio, Roberta Agrippino, Mario Annunziata, Anna Candoni, Cerrano Marco, Michele Cedrone, Maria Ciccone, Patrizia Chiusolo, Antonio Curti, Michelina Dargenio, Marzia Defina, Mario Delia, Maria Ilaria Del Principe, Mauro Endri, Carmen Fava, Fabio Forghieri, Alessandro Fiorentini, Fabio Giglio, Francesco Grimaldi, Fabio Guolo, Michela Lamanda, Monia Lunghi, Federico Lussana, Valentina Mancini, Carla Mazzone, Antonino Mulè, Crescenza Pasciolla, Matteo Piccini, Giovanna Rege Cambrin, Prassede Salutari, Lidia Santoro, Anna Maria Scattolin, Mariarita Sciumè, Elisabetta Todisco, Felicetto Ferrara, Giovanni Pizzolo, Robin Foà
Journal: Blood (2021)
Prognostic Factors Other Than Age Drive the Risk of Disease Progression in Adults with Burkitt Lymphoma Treated with DA-EPOCH-R
Authors: Rahul Lakhotia, Kieron Dunleavy, Jeremy S. Abramson, Brian K. Link, Bayard L. Powell, Christopher Melani, Andrea Nicole Lucas, Seth M. Steinberg, Jonathan W. Friedberg, Brad S. Kahl, Richard F. Little, Nancy L. Bartlett, Michelle A. Fanale, Ariela Noy, Wyndham H. Wilson, Mark Roschewski
Journal: Blood (2021)
The Combination of Anti-Tigit and Lenalidomide Promotes Synergistic Myeloma-Specific Immunity after ASCT
Authors: Simone A Minnie, Nicole S Nemychenkov, Kathleen S Ensbey, Christine R Schmidt, Gregory Driessens, Gabriela Campoy, Shuichiro Takahashi, Leona A. Holmberg, Geoffrey R Hill
Journal: Blood (2021)
Three-Year Follow-up of the Ascend Trial: Acalabrutinib Vs Rituximab Plus Idelalisib or Bendamustine in Relapsed/Refractory Chronic Lymphocytic Leukemia
Authors: Wojciech Jurczak, Andrzej Pluta, Malgorzata Wach, Daniel Lysak, Tomas Kozak, Martin Šimkovič, Iryna Kriachok, Arpad Illes, Javier de la Serna, Sean Dolan, Philip Campbell, Gerardo Musuraca, Abraham Jacob, Eric J. Avery, Jae Hoon Lee, Min Hui Wang, Ting Yu, Paolo Ghia
Journal: Blood (2021)
Three Cases of Congenital Rubella Syndrome in the Postelimination Era — Maryland, Alabama, and Illinois, 2012
Authors: Kurt Seetoo, Maria Paz Carlos, David Blythe, Leena Trivedi, Robert Myers, Tracey England, Criscelia Agee, Bill Arnold, Carolyn Dobbs, Mary McIntyre, Enrique Ramirez, Julie Morita, Saadeh Ewaidah, Wilete Ishow, Teresa Chou, Kenneth Soyemi, Albert E. Barskey, Amy Parker Fiebelkorn, Paul Lucas, Emily S. Abernathy, Joseph P. Icenogle, Gregory S. Wallace, Susan E. Reef, Yoran Grant
Journal: MMWR Morbidity and Mortality Weekly Report (2013)
Parsaclisib in Combination with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: Preliminary Results of a Phase 1/1b Study
Authors: Yucai Wang, Betsy Laplant, Rebecca L. King, Ivana N. Micallef, Stephen M. Ansell, Han W. Tun, Madiha Iqbal, Gita Thanarajasingam, Allison C. Rosenthal, David J. Inwards, Patrick B. Johnston, Luis F. Porrata, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski
Journal: Blood (2021)
Serologic Responses Following Sars-Cov-2 Vaccination and Factors Influencing It in Patients with Hematological Malignant and Non-Malignant Diseases - a Prospective Multicentric Study
Authors: Zrinka Sertić, Marko Lucijanic, Sandra Bašić-Kinda, Ranka Serventi Seiwerth, Vlatka Periša, Dubravka Sertić, Bozena Coha, Drazen Pulanic, Dragana Šegulja, Dunja Rogić, Toni Valkovic, Igor Aurer, Nadira Durakovic
Journal: Blood (2021)
Der(1;7)(q10;p10) Presents with a Unique Genetic Profile and Frequent <i>ETNK1</i> Mutations in Myeloid Neoplasms
Authors: Rurika Okuda, Yasuhito Nannya, Yotaro Ochi, Maria Creignou, Hideki Makishima, Tetsuichi Yoshizato, Yasunobu Nagata, June Takeda, Kenichi Yoshida, Masashi Sanada, Ayana Kon, Yuichi Shiraishi, Satoru Miyano, Wolfgang Kern, Constance Baer, Niroshan Nadarajah, Claudia Haferlach, Yoshiko Atsuta, Senji Kasahara, Hiroshi Handa, Shigeru Chiba, Kazuma Ohyashiki, Torsten Haferlach, Eva Hellstrom Lindberg, Seishi Ogawa
Journal: Blood (2021)
299 Broad T antigen-specific CD8+ T cell repertoire is associated with response to PD-1 blockade in virus positive merkel cell carcinoma
Authors: Ulla Hansen, Candice Church, Amalie Bentzen, Steven Fling, Nirasha Ramchurren, Suzanne Topalian, Paul Nghiem, Sine Hadrup
Journal: Journal for ImmunoTherapy of Cancer (2021)

Background Merkel cell carcinoma (MCC) is an aggressive human skin cancer primarily induced by Merkel Cell Polyomavirus (MCPyV) driven by expression of the oncogenic T antigens (T-Ags): Large T and Small T antigen. Checkpoint inhibition therapy blocking the programmed cell death protein-1 (PD-1) pathway has proven effective with a clinical response rate up to 58%, 1 highlighting the critical role of immune surveillance for tumor control. Yet, evidence for the impact of T-Ag-specific T cells following immunotherapy is still limited. Methods Potential CD8+ T cell epitopes derived from the T-Ags and the Viral capsid protein 1 (VP1) were predicted with netMHCpan 4.0 as 9- and 10-mer peptides with a rank score &lt;2 for binding to 33 different HLA class I types. Peripheral blood mononuclear cells (PBMC) were obtained from 24 MCPyV+ MCC patients prior and post anti-PD-1 therapy initiation (CITN-09/Keynote-017). T cell recognition of the MCPyV-derived peptides during therapy was evaluated using the high-throughput technology of DNA barcode labeled pMHC multimers. Phenotypic characteristics of multimer-binding T cells were evaluated for selected patients. Results Across all patients, 40 T-Ag-specific CD8+ T-cell populations were detected recognizing 31 epitopes restriction to 14 different HLA class I types. T-Ag-specific CD8+ T cells were detected in responders (complete and partial response, n=17) during therapy with a trend of increased number of responses observed after therapy initiation. Whereas only a single T-Ag-specific population was detectable in non-responders (stable and progressive disease, n=7). Moreover, the T cell repertoire after therapy initiation was significantly increased in the responder group compared to non-responder with the T-Ag-specific T cells showing an activated effector memory phenotype. Conclusions The current study indicates that the T-Ag-specific T cells are associated with clinical benefit to checkpoint inhibitor therapy. Furthermore, the broad identification of novel T-Ag-derived T cell epitopes could potentially facilitate the use of targeted T cell therapy to enhance T cell recognition and clearance of MCC in combination with checkpoint inhibition. Acknowledgements Supported by the Cancer Immunotherapy Trials Network (CITN) Reference Nghiem P, Bhatia S, Lipson E. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother cancer 2021; 9 :e002478.
Impact of <i>FLT3</i> Mutation Clearance after Front-Line Treatment with Gilteritinib Plus Azacitidine, or Gilteritinib or Azacitidine Alone in Patients with Newly Diagnosed AML: Results from the Phase 2/3 Lacewing Trial
Authors: Eunice S. Wang, Jessica K. Altman, Mark D. Minden, Ruishan Wu, Elizabeth Shima Rich, Jason E. Hill
Journal: Blood (2021)
Remembering the mission on healthcare’s path to decarbonisation
Authors: Renee N Salas
Journal: BMJ (2021)

Clinicians are driven by a common mission: to optimally improve health, prevent harm, and advance equity.This means we cannot be satisfied with just a 5% reduction in the haemoglobin A1c for diabetics or blood pressure for those with hypertension.These small reductions only serve as an intermediate step on a path to fully treating the condition in the patient in front of us.
Abstract 9972: Estimation of DAPT Study Treatment Effects in Contemporary Clinical Practice: Findings from the EXTEND-DAPT Study
Authors: Neel M Butala, Kamil Faridi, Hector Tamez, Jordan B Strom, Yang Song, Changyu Shen, Eric A Secemsky, Laura Mauri, Dean J Kereiakes, Jeptha P Curtis, C M Gibson, Robert W Yeh
Journal: Circulation (2021)

Introduction: Differences in patient characteristics, changes in treatment algorithms, and advances in medical technology could each influence the applicability of older randomized trial results to contemporary clinical practice. Objectives: To evaluate whether the Dual Antiplatelet Therapy (DAPT) Study population is different from a contemporary population of US patients receiving percutaneous coronary intervention (PCI), and to estimate the treatment effect of extended duration antiplatelet therapy after PCI in this more contemporary cohort. Methods: We compared characteristics of drug-eluting stent (DES)-treated patients randomized in the DAPT Study to a sample of more contemporary DES-treated patients in the NCDR CathPCI Registry from July 2016-June 2017. After linking trial and registry data, we employed inverse-odds of trial participation weighting to account for patient and procedural characteristics and estimated a contemporary “real-world” treatment effect of 30 vs. 12 months of DAPT after coronary stent procedures. Results: The US DES-treated trial cohort included 8864 DAPT Study patients and the registry cohort included 568,540 patients. Compared to the trial population, registry patients had more comorbidities and were more likely to present with myocardial infarction and receive 2nd generation DES. After reweighting trial results to represent the registry population, there was no longer a significant effect of prolonged DAPT on reducing stent thrombosis (reweighted treatment effect: -0.40, 95% CI: -0.99%, 0.15%), MACCE ( reweighted treatment effect: -0.52, 95% CI: -2.62%, 1.03%), or MI (reweighted treatment effect: -0.97%, 95% CI: -2.75%, 0.18%), but the increase in bleeding with prolonged DAPT persisted (reweighted treatment effect: 2.42%, 95% CI: 0.79%, 3.91%). Conclusions: Differences between patients and devices used in contemporary clinical practice compared with the DAPT Study may be associated with attenuation of benefits and relatively greater harms attributable to prolonged DAPT duration. These findings may limit applicability of average treatment effects from the DAPT Study in modern clinical practice.
Characteristics and Outcome of Adults with Severe Autoimmune Hemolytic Anemia Admitted in Intensive Care Unit: Results from a Large French Observational Study
Authors: Clara Pouchelon, Charlotte Lafont, Antoine Lafarge, Thibault Comont, Etienne Riviere, David Boutboul, Antoine Dossier, Sylvain Audia, Julien Vaidie, Marc Ruivard, Delphine Gobert, Guillaume Bonnard, Mohamed Hamidou, Corinne Haioun, Bertrand Godeau, Marc Michel
Journal: Blood (2021)